Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.
January 22, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reaffirmed an Overweight rating on Axsome Therapeutics with a price target of $108.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on AXSM's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100